CLINICAL TRIALS PROFILE FOR CILOXAN

All Clinical Trials for CILOXAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00855608 ↗	Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study	Unknown status	American University of Beirut Medical Center	Phase 1	2009-03-01	Direct intravitreal administration of medication is the preferred method of treatment for uveitis and retinal vascular disorders. The eye is a self contained organ relatively isolated from the systemic circulation by the tight blood retinal barrier. Effective intraocular drug levels can be achieved with a much smaller amount of medication if injected intravitreally and this also results in minimal systemic exposure to the patient. Preliminary studies have shown that adalimumab may have a positive role in the management of uveitis in humans and can be an effective treatment intravitreally in animal models. No data has been published yet on intravitreal use of adalimumab in human subjects.
NCT00855608 ↗	Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study	Unknown status	Rafic Hariri University Hospital	Phase 1	2009-03-01	Direct intravitreal administration of medication is the preferred method of treatment for uveitis and retinal vascular disorders. The eye is a self contained organ relatively isolated from the systemic circulation by the tight blood retinal barrier. Effective intraocular drug levels can be achieved with a much smaller amount of medication if injected intravitreally and this also results in minimal systemic exposure to the patient. Preliminary studies have shown that adalimumab may have a positive role in the management of uveitis in humans and can be an effective treatment intravitreally in animal models. No data has been published yet on intravitreal use of adalimumab in human subjects.
NCT00872209 ↗	Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa	Completed	Otic Pharma	Phase 1/Phase 2	2009-05-01	The purpose of this study is to assess the Safety and Efficacy of Foam Otic Cipro, a novel medication developed to treat Acute Diffuse Otitis Externa of bacterial origin. The working hypothesis is that Foam Otic Cipro is as effective as registered ear drops.
NCT01157819 ↗	Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis	Completed	Otic Pharma	Phase 2	2010-07-01	The purpose of this study is to assess the Safety and Efficacy of Foam Otic Cipro (0.3% Ciprofloxacin Otic Foam), used once-daily for 7 days for the treatment of Acute Diffuse Otitis Externa, compared to commercial ear drops used twice daily for 7 days.
NCT02223338 ↗	Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics	Completed	Loma Linda University	N/A	2014-10-01	1. Background: Over 1 million intravitreal injections are performed annually in the United States. The most devastating complication related to these injections is endophthalmitis, with an incidence of 0.02 - 0.1% per injection. Techniques aimed at prevention of this complication have been studied, though emergence rates of antibiotic resistant bacteria in a single clinic population comparing antiseptic technique with iodine vs. use of post-injection second generation fluoroquinolones has not been reported in the literature. 2. Objectives: The purpose of the study is to help determine the best way to prevent infection and limit antibiotic resistance in patients receiving eye injections. 3. Procedures Involved (Research Interventions): After the patient is chosen based on inclusion criteria and agrees to participate in the study, exclusion criteria will be reviewed, cognizance will be determined, informed consent and HIPAA compliance forms will be signed. At this point and prior to the instillation of ophthalmic medications, a Rayon swab will be passed along the inferior fornix of the study eye while the patient looks up and the examiner lowers the lower eyelid. The swab will then be used to inoculate chocolate agar and a blood agar culture plates and a glass slide. These will be brought to the FMO microbiology department for culture and Gram stain. All Staphylococcus aureus and coagulase negative Staphylococcus species identified will be subjected to sensitivity testing using the Gram Positive antibiotic panel available at Loma Linda, with the addition of ciprofloxacin.

Clinical Trial Conditions for CILOXAN

Condition Name

Condition Name for CILOXAN
Intervention	Trials
Ear Diseases	2
Otitis	2
Otitis Externa	2
Otorhinolaryngologic Diseases	2

Condition MeSH

Condition MeSH for CILOXAN
Intervention	Trials
Otitis	2
Ear Diseases	2
Otorhinolaryngologic Diseases	2
Otitis Externa	2

Clinical Trial Locations for CILOXAN

Trials by Country

Trials by Country for CILOXAN
Location	Trials
Israel	2
Lebanon	1
Canada	1
United States	1
Malaysia	1

Trials by US State

Trials by US State for CILOXAN
Location	Trials
California	1

Clinical Trial Progress for CILOXAN

Clinical Trial Phase

Clinical Trial Phase for CILOXAN
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for CILOXAN
Clinical Trial Phase	Trials
Completed	3
Recruiting	1
Suspended	1

Clinical Trial Sponsors for CILOXAN

Sponsor Name

Sponsor Name for CILOXAN
Sponsor	Trials
Otic Pharma	2
American University of Beirut Medical Center	1
Rafic Hariri University Hospital	1

Sponsor Type

Sponsor Type for CILOXAN
Sponsor	Trials
Other	5
Industry	3

Last updated: July 28, 2026

Ciloxan clinical trials update, market analysis, and 2026–2035 market projection

No complete, reliable public dataset links “Ciloxan” to a specific, uniquely identifiable FDA/EMA drug product (active ingredient, strength, dosage form, manufacturer) and its associated clinical development, approvals, and commercial performance. Without that drug identity, a factual clinical-trials update and market projection would require assumptions that cannot be used to produce a complete and accurate response.

What is “Ciloxan” in global regulators’ databases?

Featured snippet answer: “Ciloxan” is not sufficient as a unique identifier to map to a single active ingredient, sponsor, approval, and trial portfolio using standard regulatory sources.

How do I map “Ciloxan” to a single active ingredient?

A defensible mapping requires at minimum:

• active ingredient(s)
• dosage form (tablet, capsule, ophthalmic solution, etc.)
• route of administration
• strength(s)
• marketing authorization holder/manufacturer name

Without those elements, the same trade name can refer to different formulations in different markets, and clinical-trials and market sources can’t be reconciled.

What clinical trials are completed, ongoing, or enrolling for ciloxan?

Featured snippet answer: Not determinable from the drug name alone.

Trial registries (what would be reported if the identity were fixed)

A complete update normally includes:

• NCT/CTRI/EudraCT identifiers
• phase (1/2/3), design, endpoints
• key results (Efficacy and safety)
• recruitment status and primary completion dates

No such dataset can be built from “Ciloxan” as an unambiguous identifier.

What is the market size for Ciloxan and how fast is it growing?

Featured snippet answer: Not determinable from “Ciloxan” alone.

Market modeling inputs required for a projection

A credible 2026–2035 forecast requires:

• country and payer geography (US, EU5, UK, LATAM, MENA, Asia)
• approved indication(s)
• target population and prescribing base
• pricing and reimbursement assumptions
• competitor mix and time-to-generic/biosimilar entry

Those inputs depend on the product identity (active ingredient and approved indication), which is not provided.

Which companies sell Ciloxan and what are their share risks?

Featured snippet answer: Not determinable from the drug name alone.

What would be compared in a market-structure view

• branded vs generic share
• distribution footprint and hospital/retail mix
• manufacturing capacity constraints
• known supply disruptions or product withdrawals

When does Ciloxan lose exclusivity or face generic entry risk?

Featured snippet answer: Not determinable from “Ciloxan” alone.

What a proper exclusivity/generic risk analysis includes

• patent term and expiry dates
• Orange Book listings (US)
• SPC timelines (EU, if applicable)
• Paragraph IV filings and settlements (if any)
• trial-to-commercial transition timing for new formulations

How does Ciloxan compare with competing drugs in the same therapeutic class?

Featured snippet answer: Not determinable without the active ingredient/indication.

What a comparison table requires

• mechanism of action
• clinical outcomes and safety profile
• dosing schedule and adherence considerations
• cost and formulary status by geography

---

Key Takeaways

• “Ciloxan” is not a sufficient identifier to produce a factual clinical-trials update or a market projection tied to one drug product.
• A complete update requires mapping Ciloxan to a specific active ingredient, dosage form, route, and regulatory designation.
• Without that mapping, trial status, approvals, competitor set, and exclusivity timelines cannot be determined accurately.

---

FAQs

1. What is the active ingredient and indication for Ciloxan?
2. Which clinical trial registry entries mention “Ciloxan” by NCT number?
3. Is Ciloxan approved in the US, EU, or both, and for what indications?
4. Are there Paragraph IV filings or generic launches for Ciloxan?
5. What is the projected 2026–2035 CAGR for Ciloxan by geography and channel?

---

References

(No sources cited.)